Exelixis Balance Sheet Health
Financial Health criteria checks 6/6
Exelixis has a total shareholder equity of $2.2B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.8B and $662.8M respectively. Exelixis's EBIT is $820.3M making its interest coverage ratio -11.2. It has cash and short-term investments of $988.5M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -11.2x |
| Cash | US$988.54m |
| Equity | US$2.16b |
| Total liabilities | US$662.85m |
| Total assets | US$2.82b |
Recent financial health updates
No updates
Recent updates
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still
Nov 07With EPS Growth And More, Exelixis (NASDAQ:EXEL) Makes An Interesting Case
May 09
Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings
Apr 16Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts
Mar 13Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
Feb 21Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
Jan 09Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Oct 31
Cabozantinib's Momentum And Tactical Growth Amid Market Challenges Propel Biotech Innovation
Strong commercial performance of the cabozantinib franchise, indicating sustained revenue growth through market penetration and diversification into new indications.Exelixis Comes Up Aces
Aug 08Exelixis: With Patent Litigation Decision Due Soon, There Are Options
May 02Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28Financial Position Analysis
Short Term Liabilities: EXEL's short term assets ($1.4B) exceed its short term liabilities ($373.8M).
Long Term Liabilities: EXEL's short term assets ($1.4B) exceed its long term liabilities ($289.1M).
Debt to Equity History and Analysis
Debt Level: EXEL is debt free.
Reducing Debt: EXEL had no debt 5 years ago.
Debt Coverage: EXEL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: EXEL has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/14 00:12 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exelixis, Inc. is covered by 41 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Jason Matthew Gerberry | BofA Global Research |